|Assessment Status||Assessment process complete|
|Indication||For the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy.|
|Rapid review commissioned||07/11/2014|
|Rapid review completed||18/12/2014|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
|Full pharmacoeconomic assessment commissioned by HSE||02/04/2015|
|NCPE assessment completed||01/10/2015|
|NCPE assessment outcome||Reimbursement not recommended.|
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with CLL who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p)/TP53 mutation in patients not suitable for chemo-immunotherapy, has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.